

available at www.sciencedirect.com
journal homepage: www.europeanurology.com



European Association of Urology



Platinum Priority – Prostate Cancer
Editorial by XXX on pp. x–y of this issue

Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial

Andrew J. Armstrong^{a,*}, Ping Lin^b, Bertrand Tombal^c, Fred Saad^d, Celestia S. Higano^e, Anthony M. Joshua^{f,†}, Teresa Parli^g, Brad Rosbrook^h, Steve van Osⁱ, Tomasz M. Beer^j

^a Division of Medical Oncology and Urology, Duke Cancer Institute, Duke University, Durham, NC, USA; ^b Biostatistics, Pfizer Inc., San Francisco, CA, USA; ^c Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium; ^d Division of Urology and Urologic Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada; ^e Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ^f Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, New South Wales, Australia; ^g Clinical Development, Pfizer Inc., San Francisco, CA, USA; ^h Biostatistics, Pfizer Inc., San Diego, CA, USA; ⁱ Biostatistics, Astellas Pharma Europe BV, Leiden, The Netherlands; ^j Hematology/Medical Oncology, OHSU Knight Cancer Institute Oregon Health & Science University, Portland, OR, USA

Article info

Article history:

Accepted April 24, 2020

Associate Editor:

James Catto

Statistical Editor:

Andrew Vickers

Keywords:

Enzalutamide
Metastatic castration-resistant prostate cancer
Multivariable model
Overall survival
Prostate-specific antigen
Safety

Abstract

Background: In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Objective: To evaluate long-term benefits and risks of enzalutamide in the final pre-specified PREVAIL analysis.

Design, setting, and participants: We conducted a final 5-yr survival analysis of PREVAIL in men with chemotherapy-naïve mCRPC from the enzalutamide ($n = 689$) and placebo ($n = 693$) arms.

Outcome measurements and statistical analysis: Predictors of the primary outcome of overall survival were estimated using the Kaplan-Meier method. Long-term adverse events over time were analyzed.

Results and limitations: At the 5-yr data cutoff, 1382 of 1717 (80%) men had died. Enzalutamide reduced the hazard of death by 17% (hazard ratio 0.83; 95% confidence interval [CI] 0.75–0.93; $p < 0.001$), despite 65%, 54%, and 43% of placebo-treated patients receiving subsequent docetaxel, abiraterone, and enzalutamide, respectively. Median overall survival was 36 mo (95% CI 34–38) in the enzalutamide arm versus 31 mo (95% CI 29–34) in the placebo arm, with a median follow-up of 69 mo. Prognostic modeling showed 5-yr survival rates of 42%, 24%, and 5% for low-, intermediate-, and high-risk groups, respectively. Greater degrees of confirmed prostate-specific antigen declines (≤ 3 mo) were associated with greater 5-yr survival. A higher incidence of fatal treatment-emergent adverse events was observed with enzalutamide (6.9% vs 3.8%), with an increase in fatal cardiovascular events (1.6% vs 0.4%).

[†] Prior affiliation: Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Canada.

* Corresponding author. Division of Medical Oncology and Urology, Duke Cancer Institute, Duke University, DUMC Box 103861, Durham, NC 27710, USA. Tel.: +1-(919) 668-8797; Fax: +1-(919) 660-0178.

E-mail address: andrew.armstrong@duke.edu (A.J. Armstrong).

<https://doi.org/10.1016/j.eururo.2020.04.061>

0302-2838/© 2020 Published by Elsevier B.V. on behalf of European Association of Urology.

Please cite this article in press as: Armstrong AJ, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol (2020), <https://doi.org/10.1016/j.eururo.2020.04.061>

Conclusions: With >5 yr of follow-up, enzalutamide continued to demonstrate improved survival in patients with mCRPC despite crossover and multiple subsequent effective therapies, balanced against a slightly higher rate of fatal cardiovascular events.

PREVAIL is registered on ClinicalTrials.gov as NCT01212991.

Patient summary: We report a maintained long-term survival benefit with enzalutamide and risks with >5 yr of enzalutamide treatment and follow-up in men with metastatic prostate cancer, and identify groups of men with widely different outcomes based on clinical factors.

© 2020 Published by Elsevier B.V. on behalf of European Association of Urology.

1. Introduction

Long-term survival of men with metastatic castration-resistant prostate cancer (mCRPC) beyond 5 yr was previously very rare. In the pivotal TAX327 docetaxel trial, <5% of men lived beyond 5 yr [1–3]. Various prognostic models have been developed to estimate long-term survival using common clinical factors such as prostate-specific antigen (PSA) level, hemoglobin, alkaline phosphatase, pain, pattern of spread, lactate dehydrogenase (LDH), and other factors [1,4,5], but 5-yr survival predictability has been limited by a lack of long-term follow-up. Previously, risk groups were developed in the setting of chemotherapy that predicted 5-yr overall survival (OS) [1,2]; however, recent studies have demonstrated improved OS with potent androgen receptor inhibition in chemotherapy-naïve men with mCRPC [6,7]. Thus, updated models are needed.

We published an internally validated PREVAIL prognostic model that stratifies men with mCRPC into three risk groups with widely differing clinical outcomes and survival times [4]. Enzalutamide reduced the risk of death and radiographic progression-free survival in men in high-, intermediate-, or low-risk groups [6,8]. This model identified 11 key independent OS prognostic factors, and included a nomogram and a risk group calculator for predicting 1-, 2-, and 3-yr survival probabilities. We also confirmed the prognostic value of post-treatment PSA declines with enzalutamide for predicting OS in PREVAIL, validating work in other mCRPC settings [9–12]. The purpose of this final PREVAIL analysis is to provide long-term safety and efficacy of enzalutamide and 5-yr survival estimates based on pretreatment prognostic factors and risk groups, as well as post-treatment PSA declines.

2. Patients and methods

PREVAIL (NCT01212991), an international, randomized, double-blind, placebo-controlled, phase 3 study was reported previously [6]. Patients were randomized 1:1 to receive oral enzalutamide 160 mg or placebo once daily until intolerance, confirmed radiographic disease progression, or initiation of another therapy for prostate cancer. PREVAIL was stopped after a preplanned interim analysis revealed enzalutamide superiority compared with placebo. Eligible placebo patients could cross over to enzalutamide ($n = 234$) in an open-label extension. The crossover began on January 1, 2014. These patients were included in the placebo group for the final analysis of OS after >5 yr of follow-up.

2.1. Data sets

The primary endpoint of OS and safety analyses were updated after 1382 deaths (80%). Updated OS results utilized the full analysis set and

included data based on randomized treatment assignment (ie, the placebo arm included data following the crossover). Safety analyses included data from patients who received at least one dose of study treatment, and were reported overall and in 1-yr intervals from randomization among evaluable patients. For the updated nomogram, the data set was used as defined previously, with patients from both the enzalutamide and the placebo arm of PREVAIL divided randomly 2:1 into training and testing sets [4]. Patient characteristics and outcomes were well balanced between the training and test sets.

2.1.1. Model update

Modeling was conducted as described [4]. A multivariate Cox proportional hazard model to predict OS was developed using the training set. The hazard ratio (HR) and 95% confidence interval (CI) were computed for each potentially prognostic variable. A risk score was developed using the test and training set. Based on risk scores, the entire data set was divided at the median cut-point (high- and low-risk groups) and by tertiles (high-, intermediate-, and low-risk groups) to provide OS rates. Outcomes were reported according to the number of risk factors (point system; zero to three risk factors: low risk; four to seven risk factors: intermediate risk; and eight to 10 risk factors: high risk, not including enzalutamide treatment). OS was analyzed using Kaplan-Meier methodology. Analyses used SAS software (version 9.4; SAS Institute, Cary, NC, USA) and R glmnet and R survAUC packages (R version 3.2.2) [13].

2.2. Analysis of PSA decline

A 13-wk PSA landmark analysis was conducted to determine prognostic association with OS, excluding patients who died or were censored prior to week 13. As in a previous post hoc analysis [12], the PREVAIL enzalutamide arm was grouped as per the confirmed maximal 3-mo PSA decline from baseline: (1) no decline/<30% decline; (2) $\geq 30\%$ confirmed decline; (3) $\geq 50\%$ confirmed decline; (4) $\geq 90\%$ confirmed decline; and (5) maximal PSA decline (<0.2 ng/ml).

2.3. Statistical analysis of the final OS analysis

This preplanned final OS analysis was performed in the intent-to-treat population. Comparisons were made between the enzalutamide and placebo treatment arms. HRs were based on Cox regression models, with treatment being the only covariate.

3. Results

3.1. Patient disposition

Patients ($N = 1717$; 1715 treated) were randomized between September 2010 and September 2012. At the extended overall analysis data cutoff (September 30, 2017), 955 patients (520 from the original enzalutamide arm and 435 from the placebo arm) had entered the open-label extension or were in long-term follow-up (Supplementary

Table S1). Of these, 465 patients continued to receive enzalutamide in the open-label extension, including 234 patients who crossed over from placebo to enzalutamide and 231 patients on the enzalutamide arm who continued treatment, and 489 patients across both arms discontinued the study drug but were monitored in the long-term follow-up.

3.2. Overall survival

At the 5-yr OS analysis, there were 1382 deaths (enzalutamide, $n=689$; placebo, $n=693$). Enzalutamide reduced the hazard of death by 17% (HR 0.83; 95% CI 0.75–0.93; $p < 0.001$; Fig. 1A). At a median follow-up of 69 mo (67 mo without event), median OS was 36 mo (95% CI 34–38) in the enzalutamide arm versus 31 mo (95% CI 29–34) in the placebo arm. The 2-, 3-, and 5-yr survival rates were 71%, 49%, and 26% with enzalutamide versus 62%, 44%, and 21% with placebo (absolute risk reductions of 9%, 5%, and 5%), respectively (Supplementary Fig. S1). The enzalutamide treatment effect was generally consistent across all baseline disease-specific subgroups (Fig. 1B). In patients with baseline liver metastasis, OS benefit was not observed with enzalutamide versus placebo, but there were relatively few patients ($n=74$) with a wide CI (HR 1.12; 95% CI 0.69–1.83).

3.3. Subsequent therapy

At the data cutoff, 70% of patients in the enzalutamide arm and 85.8% in placebo arm had received one or more postbaseline antineoplastic therapies. Of patients in the enzalutamide and placebo arms, 67% and 82%, respectively, had received one of the following subsequent therapies: abiraterone acetate, cabazitaxel, docetaxel, enzalutamide, radium-223, or sipuleucel-T (Supplementary Table S2). Within this group, the most common subsequent therapy was docetaxel (enzalutamide arm, 55%; placebo arm, 65%), and the second and third most common subsequent therapies were abiraterone acetate (enzalutamide arm, 42%; placebo arm, 54%), and enzalutamide (enzalutamide arm, 6.1%; placebo arm, 43%). In the placebo arm, 68% of men received at least subsequent abiraterone or enzalutamide.

3.4. Multivariable model for predicting OS

An updated nomogram based on 5-yr OS data used 11 prognostic factors, including treatment with enzalutamide or placebo (Fig. 2). The updated model using the full data set showed a significant separation between low-risk (HR 0.25; 95% CI 0.21–0.28) and intermediate-risk (HR 0.41; 95% CI 0.36–0.46; both $p < 0.0001$) patients versus high-risk patients (Fig. 3A and Table 1). Low- and intermediate-risk patients were more likely to receive crossover treatment (Supplementary Table S3). Nomogram factors to determine predictors of survival are shown in Supplementary Table S4. Survival rates at 5 yr were 42%, 24%, and 5% for the low-, intermediate-, and high-risk groups, respectively. Numerically based risk group stratification based on baseline risk variables also provided a significant separation of OS




Fig. 1 – Long-term OS from PREVAIL. (A) Kaplan-Meier estimates of overall survival and (B) long-term survival by subgroup. Using a Bonferroni adjustment to control for multiple comparisons, $p < 0.0042$ would be considered to be statistically significant. CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; HR = hazard ratio; enza = enzalutamide; OS = overall survival; PSA = prostate-specific antigen. * Treatment by subgroup interaction p value.

between low-risk (zero to three risk variables) and intermediate-risk (four to seven risk variables) patients versus high-risk (eight to 10 risk variables) patients (Fig. 3B), which also provided strong discrimination of 5-yr survival rates ranging




Fig. 2 – Survival probability estimates. Updated nomogram to estimate survival probability. A nomogram is used to assign each of 11 prognostic factors with a point (ranging from 0 to 100) in a graphic interface, based on the estimated regression coefficients from the final multivariable Cox proportional hazard model predicting OS. The nomogram results match with the algorithm. The 1-, 2-, 3-, 4-, and 5-yr survival probability versus total points were also generated to allow the clinical partition to predict OS. The nomogram was developed using SAS enterprise and is based on the article available as <http://support.sas.com/resources/papers/proceedings13/264-2013.pdf>. Instructions to physicians: all the 11 prognostic factors should be available before using this model. Start from the second top axis by identifying the number of bone metastases. Draw a vertical line to the point's axis (top line) to represent the number of prognostic points that patients will receive for the number of bone metastases. Do the same for the other prognostic variables. Once all prognostic points for the predictors have been determined, add up the prognostic points for each prognostic variable. On the basis of the total points, one can determine the 1-yr survival probability by drawing a vertical line from the total points (x-axis) to the survival probability. The same process can be performed to estimate the 2-, 3-, 4-, and 5-yr survival probability. ALP=alkaline phosphatase; LDH=lactate dehydrogenase; NBM=number of bone metastases; NLR=neutrophil to lymphocyte ratio; OS=overall survival; prob.=probability; PoS=pattern of spread; PSA=prostate-specific antigen; TDR=time from diagnosis to randomization; ULN=upper limit of normal. ^a Equation for risk score calculation: $-0.344\text{Albumin} + 0.235\text{ALP} - 0.166\text{Hemoglobin} + 0.408\text{LDH} + 0.378\text{NLR} + 0.381\text{NBM} + 0.262\text{Pain score} + 0.707\text{PoS (liver metastasis)} + 0.204\log_e\text{PSA} - 0.003\text{TDR} + 0.389\text{Treatment}$.

Table 1 – Survival rates based on stratification by low-, intermediate-, and high-risk tertiles.

Patients	HR (95% CI)	Survival rates, % (95% CI) *		
		1 yr	3 yr	5 yr
Overall				
Low risk	0.25 (0.21–0.28)	96 (95–98)	69 (65–73)	42 (38–46)
Intermediate risk	0.41 (0.36–0.46)	93 (91–95)	51 (46–55)	24 (21–28)
High risk	REF	74 (70–77)	19 (16–23)	5 (3–7)
Enzalutamide arm				
Low risk	0.24 (0.20–0.29)	97 (94–98)	70 (65–75)	44 (38–49)
Intermediate risk	0.43 (0.35–0.51)	95 (92–97)	50 (44–56)	23 (18–29)
High risk	REF	81 (75–85)	20 (16–26)	5 (3–9)
Placebo arm				
Low risk	0.26 (0.21–0.32)	96 (92–98)	68 (62–74)	40 (33–46)
Intermediate risk	0.39 (0.33–0.47)	91 (88–94)	51 (46–57)	25 (20–30)
High risk	REF	68 (63–73)	18 (14–23)	4 (2–7)

CI = confidence interval; HR = hazard ratio; REF = reference.
 * Absolute risk reduction with treatment: Low risk: 1 yr, 1%; 3 yr, 2%; 5 yr, 4%. Intermediate risk: 1 yr, 4%; 3 yr, no reduction; 5 yr, no reduction. High risk: 1 yr, 13%; 3 yr, 2%; 5 yr, 1%.

Table 2 – Survival rates based on stratification by high (eight to 10 baseline risk variables), intermediate (four to seven baseline risk variables), and low (zero to three baseline risk variables) risks.

Patients	HR (95% CI)	Survival rates, % (95% CI)*		
		1 yr	3 yr	5 yr
Overall				
Low risk	0.17 (0.14–0.22)	95 (93–96)	64 (61–67)	37 (33–40)
Intermediate risk	0.40 (0.31–0.51)	84 (81–86)	31 (28–34)	11 (9–14)
High risk	REF	49 (37–59)	7 (2–14)	1 (0–6)
Enzalutamide arm				
Low risk	0.13 (0.10–0.18)	96 (94–98)	67 (63–72)	40 (36–45)
Intermediate risk	0.29 (0.21–0.40)	91 (88–94)	36 (31–40)	14 (11–18)
High risk	REF	54 (39–67)	4 (1–13)	0 (0–0)
Placebo arm				
Low risk	0.24 (0.16–0.36)	94 (91–96)	61 (56–65)	33 (28–38)
Intermediate risk	0.57 (0.38–0.86)	76 (71–80)	26 (21–30)	8 (6–12)
High risk	REF	38 (20–56)	12 (3–27)	4 (0–16)

CI = confidence interval; HR = hazard ratio; REF = reference.
 * Absolute risk reduction with treatment: Low risk: 1 yr, 2%; 3 yr, 6%; 5 yr, 7%. Intermediate risk: 1 yr, 15%; 3 yr, 10%; 5 yr, 6%. High risk: 1 yr, 16%; 3 yr, no reduction; 5 yr, no reduction.

from 1% to 37% (Table 2). Stratification by median risk score also showed a separation between low- and high-risk patients (HR 0.37; 95% CI 0.33–0.41; $p < 0.0001$; Fig. 3C and Table 3). Median values for baseline prognostic variables are shown in Fig. 2. Adjustment of the original 11-variable model with dichotomous values of neutrophil to lymphocyte ratio (NLR), LDH, alkaline phosphatase, and bone metastases (incremental area under the curve [iAUC] = 0.7836) to categorical variables led to slight AUC improvement (iAUC = 0.7866); further adjustment to a continuous variable for NLR led to a very slight AUC improvement (iAUC = 0.7872; Supplementary Table S5).

3.5. Prognostic association of PSA decline with OS (13-wk landmark analysis)

The HRs for OS were 0.42 (95% CI 0.34–0.53), 0.40 (95% CI 0.32–0.50), and 0.32 (95% CI 0.25–0.41) for confirmed 3-mo enzalutamide-treatment PSA declines of $\geq 30\%$, $\geq 50\%$, and $\geq 90\%$, respectively, versus no decline or $< 30\%$ decline

(Fig. 3D) as the reference group. The HR for OS was 0.12 (95% CI 0.07–0.22) for men with PSA < 0.2 ng/ml. The 5-yr OS rates were 9%, 30%, 31%, 37%, and 67% for men with no PSA decline to $< 30\%$ PSA decline ($n = 94$), $\geq 30\%$ decline ($n = 701$), $\geq 50\%$ PSA decline ($n = 639$), $\geq 90\%$ PSA decline ($n = 307$), and PSA < 0.2 ng/ml ($n = 37$), respectively (Table 4).

3.6. Safety

Treatment-emergent adverse events (TEAEs) were reported as the primary reason for discontinuation in 9.1% of enzalutamide and 6.0% of placebo patients (Table 5). The median duration of therapy and adverse event reporting was 17.7 mo for the enzalutamide (range, 0.2–78.5) and 4.6 mo for the placebo (range, 0.1–34.5) group. The most frequently reported TEAEs in the enzalutamide arm were fatigue, select gastrointestinal events, hypertension, and fractures. Reported incidences for fatigue in the enzalutamide arm were highest during the 1st year (44%) and then generally decreased at 1– < 2 (15.1%), 2– < 3 (11.9%), 3– < 4

Table 3 – Survival rates based on stratification by median risk score.

Patients	HR (95% CI)	Survival rates, % (95% CI)*		
		1 yr	3 yr	5 yr
Overall				
Low risk	0.37 (0.33–0.41)	96 (95–97)	67 (63–70)	38 (35–42)
High risk	REF	79 (77–82)	26 (24–30)	9 (7–11)
Enzalutamide arm				
Low risk	0.36 (0.31–0.42)	97 (95–98)	67 (62–71)	39 (35–44)
High risk	REF	85 (81–88)	27 (22–31)	9 (6–12)
Placebo arm				
Low risk	0.38 (0.33–0.45)	96 (93–97)	66 (61–71)	36 (31–42)
High risk	REF	75 (71–79)	26 (22–30)	9 (7–12)

CI = confidence interval; HR = hazard ratio; REF = reference.

* Absolute risk reduction with treatment: Low risk: 1 yr, 1%; 3 yr, 1%; 5 yr, 3%. High risk: 1 yr, 10%; 3 yr, 1%; 5 yr, no reduction.

Table 4 – Survival rates based on the degree of confirmed PSA decline at week 13 and best overall PSA decline.

Patients ^a	n	Survival rates, % (95% CI)		
		1 yr	3 yr	5 yr
PSA <0.2 ng/ml	37	97 (82–100)	84 (67–92)	67 (49–80)
PSA ≥90% confirmed decline	307	98 (95–99)	66 (60–71)	37 (32–43)
PSA ≥50% confirmed decline	639	96 (94–97)	58 (54–62)	31 (28–35)
PSA ≥30% confirmed decline	701	96 (94–97)	56 (52–59)	30 (27–33)
No PSA decline to <30% confirmed decline	94	82 (73–88)	25 (17–35)	9 (5–17)
All enzalutamide patients	819	94 (92–95)	51 (48–55)	27 (24–30)
Best overall PSA decline				
PSA <0.2 ng/ml	100	99 (93–100)	91 (83–95)	71 (61–79)
PSA ≥90% confirmed decline	376	98 (96–99)	69 (64–73)	42 (37–47)
PSA ≥50% confirmed decline	636	96 (95–98)	58 (54–62)	31 (28–35)
PSA ≥30% confirmed decline	691	96 (94–97)	56 (52–59)	30 (26–33)
No PSA decline to <30% confirmed decline	30	80 (61–90)	32 (17–49)	11 (3–25)
All enzalutamide patients	872	92 (90–93)	49 (46–53)	26 (23–29)

CI = confidence interval; PSA = prostate-specific antigen.

^a Patients who died or were censored prior to week 13 were excluded.

(9.7%), 4–<5 (8.7%), and ≥5 (2.3%) yr (Fig. 4 and Supplementary Table S6). Fracture incidences were 4.7%, 5.7%, 5.4%, 5.6%, 4.3%, and 2.3% in these time frames, respectively. The incidence of other TEAEs was highest at <1 yr, and decreased or remained stable for subsequent yearly rates. For the most commonly reported TEAEs, a lower incidence was generally observed in the placebo group versus the enzalutamide group, and mostly reported in the first couple of years. Seizures were rare in both groups (<1%) over time (Fig. 4 and Supplementary Table S6).

Data on cardiovascular events in this extended follow-up period suggested that men treated with enzalutamide may be at an increased risk of cardiovascular events compared with the placebo group (Supplementary Table S7). Cardiovascular events (grade ≥3) were higher in men ≥75 yr of age treated with enzalutamide versus placebo (8.8% vs 2.4%) versus younger men (4.3% vs 2.0%) and were higher in men with and without established cardiovascular risk factors. The presence of known baseline cardiovascular risk factors was associated with an increased risk of cardiovascular events in the placebo group (2.6% vs 1.1%) and in placebo patients who received subsequent enzalutamide (7.2% vs 3.0%). Cardiovascular TEAEs resulting in death were higher with enzalutamide ($n = 14$, 1.6%) versus placebo ($n = 3$, 0.4%;

Supplementary Table S8). Cardiovascular TEAEs resulting in enzalutamide-related death were observed in two patients (cardiac failure, $n = 1$; congestive cardiac failure, $n = 1$) and placebo-related death in one patient (pulmonary hemorrhage and tumor embolism; Supplementary Table S9).

4. Discussion

In this long-term PREVAIL analysis, enzalutamide maintained a long-term survival advantage over placebo despite the majority of placebo-treated men (68%) receiving subsequent enzalutamide or abiraterone. We provide rates of 5-yr survival according to treatment as well as according to pretreatment patient characteristics and post-treatment confirmed PSA declines. Such data provide clinical utility by establishing realistic and updated expectations for patients and providers around prognosis based on individual patient-specific factors and response to therapy. Men treated with enzalutamide had widely variable 5-yr survival rates. Using the risk score model, low-risk patients with mCRPC treated with enzalutamide had 5-yr survival of 40%, while high-risk patients with mCRPC treated with enzalutamide had 5-yr survival of 0%. Following treatment, prognosis can be updated based on an individual patient's




Fig. 3 – Analysis of OS based on the 11-variable model stratified by low-, intermediate-, and high-risk score tertiles: (A) analysis of OS based on the 11-variable model stratified by low-, intermediate-, and high-risk tertiles; (B) analysis of OS in patients stratified by high (eight to 10 baseline risk variables), intermediate (four to seven risk variables), and low (zero to three risk variables) risks based on the number of risk variables present at baseline; (C) analysis of overall survival based on the 11-variable model stratified by median risk score; and (D) Kaplan-Meier plot of overall survival by level of greatest confirmed PSA decline from baseline within the first 3 mo of treatment with enzalutamide (excluding patients who died or were censored prior to week 13). Survival plots are shown without making comparisons between treatment groups but for purposes of providing prognostic information. CI = confidence interval; enza = enzalutamide; Int. = intermediate; OS = overall survival; PSA = prostate-specific antigen; REF = reference.

Table 5 – Long-term safety summary.

	Enzalutamide (n = 871)				Placebo (n = 844)			
TEAEs, n (%)								
Overall TEAEs	857 (98)				791 (94)			
Grade ≥3 TEAEs	462 (53)				318 (38)			
TEAEs leading to death	60 (6.9)				32 (3.8)			
Any serious TEAEs	382 (44)				229 (27)			
TEAEs leading to treatment discontinuation	79 (9.1)				51 (6.0)			
TEAEs leading to study drug discontinuation	208 (24)				218 (26)			
Fatal CV TEAEs	14 (1.6)				3 (0.4)			
Drug-related fatal CV AEs	2 (0.2)				0			
	Grade 1/2	Grade 3/4	Grade 5	All	Grade 1/2	Grade 3/4	Grade 5	All
TEAEs of special interest, n (%)								
Fatigue	418 (48)	36 (4.1)	0	454 (52)	274 (32)	25 (3.0)	0	299 (35)
Select gastrointestinal events ^a	404 (46)	20 (2.3)	0	424 (49)	342 (41)	12 (1.4)	0	354 (42)
Hypertension	78 (9.0)	76 (8.7)	0	154 (18)	18 (2.1)	23 (2.7)	0	41 (4.9)
Fall	122 (14)	20 (2.3)	0	142 (16)	39 (4.6)	6 (0.7)	0	45 (5.1)
Fractures	96 (11)	42 (4.8)	0	138 (16)	28 (3.3)	17 (2.0)	0	45 (5.3)
Hypersensitivity ^b	79 (9.1)	4 (0.5)	1 (0.1)	84 (9.6)	48 (5.7)	2 (0.2)	0	50 (5.9)
Select CV events ^c	28 (3.2)	32 (3.7)	6 (0.7)	66 (7.6)	12 (1.4)	4 (0.5)	1 (0.1)	17 (2.0)
Major CV events ^d	12 (1.4)	31 (3.6)	5 (0.6)	48 (5.5)	9 (1.1)	7 (0.8)	1 (0.1)	17 (2.0)
Renal impairment ^e	24 (2.8)	15 (1.7)	0	39 (4.5)	26 (3.1)	10 (1.2)	2 (0.2)	38 (4.5)
Hepatic impairment ^f	21 (2.4)	12 (1.4)	1 (0.1)	34 (3.9)	18 (2.1)	4 (0.5)	1 (0.1)	23 (2.7)
Loss of consciousness	0	20 (2.3)	0	20 (2.3)	1 (0.1)	9 (1.1)	0	10 (1.2)
Venous thromboembolic events	9 (1.0)	7 (0.8)	1 (0.1)	17 (2.0)	8 (0.9)	9 (1.1)	0	17 (2.0)
Neutropenia	9 (1.0)	5 (0.6)	0	14 (1.6)	2 (0.2)	3 (0.4)	0	5 (0.6)
Seizures	0	2 (0.2)	0	2 (0.2)	1 (0.1)	0	0	1 (0.1)
Hallucinations	1 (0.1)	0	0	1 (0.1)	1 (0.1)	0	0	1 (0.1)
Mental impairment ^g	0	0	0	0	0	0	0	0

AE=adverse event; CV=cardiovascular; MedDRA=Medical Dictionary for Regulatory Activities; SMQ=Standardized MedDRA Query; TEAE=treatment-emergent adverse event.

^a Includes constipation, diarrhea, nausea, and vomiting.

^b Includes prespecified narrow SMQ of “hypersensitivity.”

^c Includes prespecified narrow SMQs of “myocardial infarction” and “other ischemic heart disease.”

^d Includes narrow SMQs of “myocardial infarction,” “hemorrhagic cerebrovascular conditions,” and “ischemic cerebrovascular conditions.”

^e Includes broad SMQ of “acute renal failure.”

^f Includes narrow SMQ of “drug-related hepatic disorders comprehensive search.”

^g Includes all preferred terms under the MedDRA High Level Group Term “mental impairment disorders.”




Fig. 4 – TEAEs of special interest by date of onset by year. CV = cardiovascular; TEAE = treatment-emergent adverse event.

sensitivity to enzalutamide therapy, with 5-yr survival rates ranging from 9% to 67%. These data, in the form of an online calculator (see <https://www.mdcalc.com/prevail-model-prostate-cancer-survival>) can provide valuable

patient-specific information to guide communications and goals for care.

Enzalutamide maintained a survival advantage despite crossover of the majority of patients to life-prolonging

therapies, including abiraterone, docetaxel, and enzalutamide. This suggests that early use of potent androgen receptor inhibition may be beneficial to some men in this setting by delaying further metastatic spread. In the non-mCRPC setting, potent androgen receptor inhibition has also delayed metastatic spread, with the possibility of improved survival, pending long-term follow-up [14,15].

Enzalutamide was found to be safe and effective overall, with manageable long-term toxicities. We found a higher rate of treatment-related deaths, particularly cardiovascular deaths, with enzalutamide versus placebo and a higher rate of clinically significant fractures, falls, fatigue, cardiovascular events, and hypertension, which may lead to increases in mortality and morbidity over time. Based on these findings, we recommend cardiovascular risk assessment prior to starting hormonal therapy and over time, and for providers, to address known heart disease risk factors. We further recommend that risk factors such as these be evaluated at baseline and over time in future androgen receptor inhibition clinical trials. Exercise may be the most critical area for intervention because of its benefits in supporting heart health, maintaining a healthy body weight, reducing the risk of sarcopenia and metabolic syndrome, reducing hot flashes, improving bone health, and preventing fractures [16–18]. We have shown [19] that a proactive diet and exercise program may reduce many of these adverse events in men treated with androgen deprivation therapy with or without enzalutamide, and that an individualized exercise training program may be a low-cost and effective therapy to mitigate many adverse effects of hormonal therapies [20,21]. The use of denosumab or zoledronic acid is another important consideration in this setting to ensure bone health and for fracture prevention, as demonstrated in the PEACE III trial [22].

One limitation is the lack of integrated biomarker data for the development of a clinical-genomic risk group system. Certain biomarkers, such as AR-V7, TP53 alterations and RB1 loss, DNA repair alterations, androgen receptor gain and genomic structural rearrangements, enumeration of circulating tumor cells, circulating androgen levels, ctDNA quantification, and other molecular drivers of aggressive disease biology, were not assessed in the PREVAIL study [23–28]. Future analyses from independent data sets should examine these clinical prognostic models in the context of mutational information. Additionally, when this study was carried out, upfront docetaxel or potent androgen receptor inhibition was not used as the standard of care in de novo metastatic hormone-sensitive disease. It remains unclear whether models described herein can be applied to patients with metastatic hormone-sensitive prostate cancer when progressing to mCRPC.

5. Conclusions

These data provide important prognostic information to healthcare providers who commonly use androgen receptor inhibitors, such as enzalutamide, for the treatment of patients with chemotherapy-naïve mCRPC. With >5 yr of

follow-up, enzalutamide continued to demonstrate OS benefit versus placebo in patients with asymptomatic or mildly symptomatic mCRPC, despite placebo crossover and multiple subsequent therapies. Survival benefits were observed across all patient subgroups with no treatment-risk group interactions noted. Five-year survival benchmarks for this disease state and therapy based on patient characteristics and response to enzalutamide therapy were established. We hope that this information will be useful for providers and patients (see Supplementary Fig. S2 for summary infographic). There is a need to study patients with mCRPC with multiple high-risk features including liver metastases in future clinical trials, as they continue to experience poor 5-yr survival rates regardless of therapy.

A portion of these data were presented at the 34th Annual European Association of Urology (EAU) Congress; March 15–19, 2019; Barcelona, Spain.

Author contributions: Andrew J. Armstrong had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Armstrong, Tombal, Higano, Beer.

Acquisition, of data: All authors.

Analysis and interpretation of data: All authors.

Drafting of the manuscript: Armstrong.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Rosbrook.

Obtaining funding: Parli.

Administrative, technical, or material support: Parli.

Supervision: Armstrong, Tombal, Higano, Beer.

Other: None.

Financial disclosures: Andrew J. Armstrong certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Andrew J. Armstrong has received honoraria from Dendreon, Janssen Oncology, and Sanofi; has served as a consultant for Dendreon, Sanofi, Astellas, Bayer, Janssen Biotech, Medivation, Novartis, and Pfizer; has been a member of the Speakers Bureau for Dendreon, Sanofi, and Bayer; has received money for travel/accommodations expenses from Dendreon, Astellas, Bayer, and Janssen Biotech; has received research funding from Dendreon, Medivation, Novartis, Pfizer, Active Biotech, Astellas, Bristol-Myers Squibb, Gilead Sciences, and Roche-Genentech; has received grant money from Janssen Oncology; and has received royalties from a circulating tumor cell novel capture technology. Ping Lin: former employee of Pfizer Inc. Bertrand Tombal has received honoraria from Amgen, Astellas, Bayer, Ferring, Janssen, Pfizer, and Sanofi; has served as a consult for Bayer, Ferring, Janssen, Sanofi, Astellas, Steba Biotech, and Takeda; has received money for travel/accommodation expenses from Bayer, Ferring, Janssen, Sanofi, and Astellas; and has received research funding from Ferring. Fred Saad has received consultant and grant/research support from Astellas, AstraZeneca, Bayer, BMS, Janssen, Pfizer, and Sanofi. Celestia S. Higano has received honorarium from Genentech; has served as a consult for Aptevio, Asana, Astellas Pharma, Bayer, Blue Earth Diagnostics, Churchill Pharma, Clovis Oncology, Dendreon, Endocyte, Ferring, Hinova, Janssen; Myriad Genetics, Orion Corporation, Pfizer, and Tolmar; has received research funding from Aptevio (Inst),

Aragon Pharmaceuticals (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), Clovis (Inst), Dendreon (Inst), eFFECTOR Therapeutics (Inst), Emergent BioSolutions (Inst), Ferring (Inst), Genentech (Inst), Hoffman-Laroche (Inst), Medivation (Inst), and Pfizer (Inst); has received travel, accommodations, expenses from Astellas Pharma, Bayer, Blue Earth Diagnostics, Clovis Oncology, Ferring, Genentech, Hinova, Janssen, Myriad Genetics, Orion, and Pfizer. Anthony M. Joshua has received research funding from Aptevio Therapeutics (Inst), Astellas Pharma (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Janssen Oncology (Inst), Lilly (Inst), MacroGenics (Inst), Mayne Pharma (Inst), Merck Sharp & Dohme (Inst), and Roche/Genentech (Inst). Teresa Parli: former employee of Pfizer Inc. Brad Rosbrook: employee of Pfizer Inc. Steve van Os: employee of Astellas Pharma, Inc. Tomasz M. Beer has served as a consult for AbbVie, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Clovis Oncology, GlaxoSmithKline, Janssen Biotech, Janssen Japan, Merck, and Pfizer; has received grant/research support from Alliance Foundation Trials, Astellas, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc., Janssen Research & Development, Medivation, OncoGenex, Sotio, and Theraclone Sciences-OncoResponse; and holds stock ownership in Salarius Pharmaceuticals and Arvinas, Inc.

Funding/Support and role of the sponsor: The PREVAIL trial and analyses presented in this article were sponsored by Pfizer Inc. (New York, NY) and Astellas Pharma, Inc. (Northbrook, IL), the co-developers of enzalutamide. Medical writing and editorial support funded by both sponsor companies were provided by Ira Mills, PhD, and Michele Salernitano of Ashfield Healthcare Communications. Authors who are employed by the study sponsors, Pfizer Inc., and Astellas Pharma, Inc., were involved in the design and conduct of the study: collection (ie, management, analysis, and interpretation of the data; preparation of the manuscript; and the decision to submit the manuscript for publication).

Data Sharing Statement: Upon request, and subject to certain criteria, conditions, and exceptions (see <https://www.pfizer.com/science/clinical-trials/trial-data-and-results> for more information), Pfizer will provide access to individual deidentified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and/or EU or (2) in programs that have been terminated (ie, development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 mo after study completion. The deidentified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.eururo.2020.04.061>.

References

- [1] Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. *Clin Cancer Res* 2007;13:6396–403.
- [2] Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. *Eur J Cancer* 2010;46:517–25.
- [3] Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004;351:1502–12.
- [4] Armstrong AJ, Lin P, Higano CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. *Ann Oncol* 2018;29:2200–7.
- [5] Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. *J Clin Oncol* 2016;34:1652–9.
- [6] Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014;371:424–33.
- [7] Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med* 2013;368:138–48.
- [8] Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. *Eur Urol* 2017;71:151–4.
- [9] Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. *J Natl Cancer Inst* 2006;98:516–21.
- [10] Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. *J Clin Oncol* 2007;25:3965–70.
- [11] Renscigno P, Lorente D, Bianchini D, et al. Prostate-specific antigen decline after 4 weeks of treatment with abiraterone acetate and overall survival in patients with metastatic castration-resistant prostate cancer. *Eur Urol* 2016;70:724–31.
- [12] Armstrong AJ, Lin P, Higano CS, et al. Prognostic association of prostate-specific antigen decline with clinical outcomes in men with metastatic castration-resistant prostate cancer treated with enzalutamide in a randomized clinical trial. *Eur Urol Oncol* 2019;2:677–84.
- [13] R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria <http://www.R-project.org/2016>
- [14] Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *N Engl J Med* 2018;378:2465–74.
- [15] Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. *N Engl J Med* 2018;378:1408–18.
- [16] Cormie P, Galvao DA, Spry N, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. *BJU Int* 2015;115:256–66.
- [17] Finlay A, Wittert G, Short CE. A systematic review of physical activity-based behaviour change interventions reaching men with prostate cancer. *J Cancer Surviv* 2018;12:571–91.
- [18] Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: an update meta-analysis. *Medicine (Baltimore)* 2017;96:e7368.
- [19] Freedland SJ, Howard L, Allen J, et al. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial. *Prostate Cancer Prostatic Dis* 2019;22:428–37.
- [20] Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer

- without bone metastases: a randomized controlled trial. *J Clin Oncol* 2010;28:340–7.
- [21] Harrison MR, Khouiri MG, Armstrong AJ, et al. PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET). *J Clin Oncol* 2019;37(Suppl. 7S):281.
- [22] Tombal B, Lortot Y, Saad F, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. *J Clin Oncol* 2019;37(Suppl):5007.
- [23] Annala M, Vandekerckhove G, Khalaf D, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. *Cancer Discov* 2018;8:444–57.
- [24] Armstrong AJ, Halabi S, Luo J, et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. *J Clin Oncol* 2019;37:1120–9.
- [25] de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008;14:6302–9.
- [26] De Laere B, Oeyen S, Mayrhofer M, et al. TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2019;25:1766–73.
- [27] Mehra N, Dolling D, Sumanasuriya S, et al. Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA). *Eur Urol* 2018;74:283–91.
- [28] Ryan CJ, Molina A, Li J, et al. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. *J Clin Oncol* 2013;31:2791–8.